Abraxane Drives Growth In Potential $1bn Pancreatic Cancer Market
This article was originally published in Scrip
The year-on-year growth rate of pancreatic cancer drug sales will be around 10% until peaking at around $1bn in 2023. The growth will be driven primarily by strong uptake of Celgene's Abraxane (nab-paclitaxel albumin bond) for the treatment of advanced pancreatic cancer, according to a recent forecast by Datamonitor Healthcare.
Register for our free email digests: